Effects of pentostatin injection: A Synthesis of Findings from 30 Studies

  1. Home
  2. Effects of pentostatin injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of pentostatin injection: A Synthesis of Findings from 30 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of pentostatin injection: A Synthesis of Findings from 30 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Pentostatin, a drug that inhibits the enzyme adenosine deaminase (ADA), has shown promise in the treatment of various blood cancers, immune diseases, and complications after transplantation. Research has shown that pentostatin administration can be effective in treating blood cancers like hairy cell leukemia, T-cell prolymphocytic leukemia, graft-versus-host disease (GVHD), and adult T-cell leukemia (ATL). 4 , 7 , , , 10 , 12 , 16 , 9 Furthermore, pentostatin has also demonstrated effectiveness in suppressing skin graft rejection and improving resistance to malaria infection in mice. 29 , 21 These findings suggest that pentostatin possesses diverse effects, including inhibiting the growth of specific cancer cells, activating immune cells, and suppressing immune responses.

Benefits and Risks

Benefits Summary

Pentostatin has shown efficacy in treating various blood cancers. 4 , 7 , , , 10 , 12 , 16 , 9 It also exhibits benefits in suppressing skin graft rejection and enhancing resistance to malaria infection in mice. 29 , 21 For some individuals with blood cancers, pentostatin could potentially be an effective treatment option.

Risk Summary

Common side effects of pentostatin include infections, thrombocytopenia, anemia, nausea, vomiting, rash, and stomatitis. 23 , 18 , 8 , 6 , 20 Notably, due to its immunosuppressive effects, pentostatin increases the risk of infections. 5 , 6 When considering pentostatin administration, it's crucial to thoroughly understand both the risks and benefits, and consult a healthcare professional for guidance.

Comparison between Studies

Commonalities

These studies consistently point to the potential of pentostatin administration in treating various blood cancers and immune diseases. Additionally, a common finding across these studies is that pentostatin exhibits the ability to activate and suppress immune cells.

Differences

The studies differ in terms of the specific diseases investigated, pentostatin administration methods, dosages, and the level of detail provided regarding side effects. Some studies provide more in-depth information about pentostatin's adverse effects.

Consistency and Discrepancies in Results

While these studies show consistency in their findings, some discrepancies also exist. For example, pentostatin has demonstrated strong efficacy against certain blood cancers, but its effectiveness against other types of blood cancers may be limited. 12 Additionally, the reported frequency and nature of pentostatin's side effects vary across studies. These differences could be attributed to variations in patient populations, administration methods, and dosages used in different research studies.

Cautionary Notes on Real-World Applications

Pentostatin holds promise as a treatment option for various blood cancers and immune diseases. However, its immunosuppressive properties increase the risk of infections. 5 , 6 It is important to remember that side effects like thrombocytopenia, anemia, nausea, vomiting, rash, and stomatitis have been reported. 23 , 18 , 8 , 6 , 20 When considering pentostatin therapy, it is crucial to be fully informed about both the risks and benefits and seek guidance from a medical professional.

Limitations of Current Research

More research is needed to fully understand the effects and side effects of pentostatin. Further investigation is essential for understanding the long-term implications of pentostatin use, its effectiveness against various diseases, and the determination of optimal administration methods and dosages. Additional research is also required to explore the combined effects of pentostatin with other therapeutic approaches.

Future Research Directions

While pentostatin shows promise as a treatment for various blood cancers and immune diseases, there are still many unanswered questions regarding its effects and side effects. Future research should focus on elucidating the long-term impact of pentostatin, its efficacy against a wider range of diseases, and the identification of optimal administration methods and dosages. Exploring the combined effects of pentostatin with other treatments is also essential.

Conclusion

Pentostatin has demonstrated potential in treating various blood cancers and immune diseases. However, its immunosuppressive nature increases the risk of infections. When considering pentostatin therapy, it's crucial to fully comprehend both the risks and benefits and consult with a healthcare professional for guidance.

Keywords
Benefit Keywords
Good tolerance
1
High sensitivity detection
Improved pentostatin analysis
2
CL treatment
3
Effective treatment
Well-tolerated
4
Abrogate anti-immunotoxin reactivity
5
Complete remission
HCL treatment
6
Improved graft-versus-host disease
7
Hairy cell leukemia treatment
T-cell lymphoma treatment
8
Articular symptom relief
Complete remission
9
DCF LGL leukemia efficacy
DCF Sézary syndrome efficacy
DCF T-PLL efficacy
DCF safety
10
Palliates hairy cell leukemia
Prevents relapse
Well tolerated
11
Effective for hairy cell leukemia
12
Effective for hairy cell leukemia
13
Treat hairy cell leukemia
14
Recovery of blood cells
Remission
16
Complete remission
17
CTCL treatment
Lymphoma treatment
18
Augments immune response
Treats malaria
21
Decidual protection
22
CLL treatment
23
Tumor cell purging
24
Enhanced natural killer cell activity
25
Adult T-cell leukemia treatment
27
Immunosuppression
29
Increase REM sleep
Increase deep slow-wave sleep
30
Risk Keywords
Liver enzyme elevation
Platelet reduction
1
Toxicity
3
Poor results subcutaneous
4
Immune suppression
Secondary malignancy
Stem cell toxicity
6
Infections
Liver function abnormalities
Lymphopenia
Thrombocytopenia
7
CD4 suppression
Granulocytopenia
Herpes zoster
Nausea
Renal insufficiency
8
Fever
Intense headaches
Leukemic cell infiltration
Refractory arthralgia
9
Relapse without maintenance
11
Death
Infectious complications
Relapse
12
May not eradicate the clone
Suppress T cells
14
Embryotoxicity
15
Appetite loss
Fatigue
Fever
Nausea
Skin rash
Vomiting
16
Palliative and transient
Unsatisfactory effects
17
Fatal toxicities
18
Thymocyte destruction
19
Bone formation
Bone marrow injury
Myelostromal proliferation
20
Impaired T-cell function
21
Embryonic development arrest
22
anemia
infections
thrombocytopenia
23
Decreased lymphocytes
Decreased spleen weight
Depressed mixed lymphocyte response
Suppressed lymphoproliferative responses
25
Body weight
Immune function
Spleen weight
Thymus weight
26
Gastrointestinal toxicity
27
Lymphocyte Development Inhibition
28
Lymphocytotoxicity
29
Literature analysis of 30 papers
Positive Content
21
Neutral Content
3
Negative Content
6
Article Type
2
0
0
3
30
1.

Tolerance and biological activity of pentosan polysulfate after intramuscular or subcutaneous administration for ten days in human volunteers.

Author: SiéP, AlbaredeJ L, RobertM, BoulouxC, LansenJ, ChigotC, CorrellS, ThouvenotJ P, BoneuB

Good tolerance
Liver enzyme elevation
Platelet reduction

Pentosan polysulfate (PPS) is a drug that can be used to treat certain medical conditions. This study investigated the tolerance and pharmacological activity of PPS in 30 healthy volunteers. PPS was well tolerated, with the most common side effects being increased transaminase levels and decreased platelet counts. The study found that PPS significantly prolonged the activated partial thromboplastin time (APTT) and induced a weak but significant circulating anti-Xa activity.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

The successful use of radiofrequency-induced heat therapy for cutaneous leishmaniasis: a review.

Author: DavidJohn R

CL treatment
Toxicity

Pentavalent antimonials are the gold standard for treating cutaneous leishmaniasis (CL), but they are toxic. This abstract highlights the successful introduction of radiofrequency-induced heat therapy as a safer and more effective treatment option.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.

Author: DeardenClaire E, KhotAmit, ElseMonica, HamblinMike, GrandEffie, RoyAshok, HewamanaSaman, MatutesEstella, CatovskyDaniel

Effective treatment
Well-tolerated
Poor results subcutaneous

Intravenous alemtuzumab is an effective treatment for T-cell prolymphocytic leukemia (T-PLL), but subcutaneous administration is not effective. Alemtuzumab is the treatment of choice for previously untreated T-PLL.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.

Author: MossobaMiriam E, OndaMasanori, TaylorJustin, MasseyPaul R, TreadwellShirin, SharonElad, HassanRaffit, PastanIra, FowlerDaniel H

Abrogate anti-immunotoxin reactivity

This study hypothesized that a new immune depletion regimen consisting of pentostatin plus cyclophosphamide would abrogate anti-immunotoxin reactivity. The study used a well-established murine model and aimed to demonstrate the effectiveness of the regimen in reducing neutralizing antibody production.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Purine analog toxicity in patients with hairy cell leukemia.

Author: TadmorTamar

Complete remission
HCL treatment
Immune suppression
Secondary malignancy
Stem cell toxicity

The toxicity of cladribine and pentostatin in the treatment of hairy cell leukemia was reviewed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Pentostatin in steroid-refractory acute graft-versus-host disease.

Author: Bolaños-MeadeJavier, JacobsohnDavid A, MargolisJeffrey, OgdenAdam, WientjesM Guillaume, ByrdJohn C, LucasDavid M, AndersViki, PhelpsMichele, GreverMichael R, VogelsangGeorgia B

Improved graft-versus-host disease
Infections
Liver function abnormalities
Lymphopenia
Thrombocytopenia

Pentostatin, a potent inhibitor of adenosine deaminase, has activity in patients with steroid-refractory acute graft-versus-host disease (aGVHD) with 63% of patients achieving a complete response and 13% achieving a partial response.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Historical ArticleA research paper that analyzes past events and developments using primary sources and examines them from a historical perspective.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Pentostatin (Nipent) in T-cell lymphomas.

Author: KurzrockR

Hairy cell leukemia treatment
T-cell lymphoma treatment
CD4 suppression
Granulocytopenia
Herpes zoster
Nausea
Renal insufficiency

Pentostatin showed significant response rates in heavily pretreated patients with cutaneous and peripheral T-cell lymphomas, suggesting its potential as an active agent in this group of diseases.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

[Effective pentostatin-based treatment of adult T cell leukemia in a patient with severe arthritis].

Author: MiyagawaA, SakabeH, AmakataY, InoueT, AndohA, HodoharaK, FujiyamaY, BambaT

Articular symptom relief
Complete remission
Fever
Intense headaches
Leukemic cell infiltration
Refractory arthralgia

A 48-year-old woman with adult T-cell leukemia experienced refractory arthralgia, headaches, and fever. The patient achieved complete remission following pentostatin treatment. However, six months later, her symptoms returned. She again achieved complete remission following another pentostatin treatment. This case highlights the potential effectiveness of pentostatin in treating refractory symptoms associated with adult T-cell leukemia.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Japanese

10.

The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.

Author: MerciecaJ, MatutesE, DeardenC, MacLennanK, CatovskyD

DCF LGL leukemia efficacy
DCF Sézary syndrome efficacy
DCF T-PLL efficacy
DCF safety

DCF is effective as a single agent in T-PLL, Sézary syndrome, and LGL leukemia, but has low activity in other T-cell disorders.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Long term results with 2'deoxycoformycin in hairy cell leukemia.

Author: CatovskyD, MatutesE, TalaveraJ G, O'ConnorN T, JohnsonS A, EmmettE, CorbettL, SwansburyJ

Effective for hairy cell leukemia
Death
Infectious complications
Relapse

The study investigated the efficacy and safety of 2'-deoxycoformycin (DCF) in treating 159 patients with hairy cell leukemia (HCL). DCF achieved a response rate of 74.3% for complete remission and 22.3% for partial remission, with a median survival of 5 years. Lymphopenia and neutropenia were common side effects, but infectious complications were less frequent. The study concluded that DCF is a safe and effective treatment option for HCL.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Comparison of pentostatin and alpha interferon in splenectomized patients with active hairy cell leukemia: an intergroup study. Cancer and Leukemia Group B and South-West Oncology Group.

Author: RaiK R

Effective for hairy cell leukemia

Pentostatin and alpha interferon (aIF) were compared in treating splenectomized patients with active HCL. Pentostatin resulted in a higher response rate and faster remission, with remissions lasting significantly longer compared to aIF. No unusual toxicities were observed with either drug.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

14.

Long-term follow-up of patients with hairy cell leukaemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration.

Author: ThalerJ, GrünewaldK, GattringerC, HoA D, WeyrerK, DietzeO, StauderR, FluckingerT, LangA, HuberH

Treat hairy cell leukemia
May not eradicate the clone
Suppress T cells

2'-deoxycoformycin (pentostatin, DCF) treatment for hairy cell leukaemia (HCL) is effective in inducing remission, but does not eradicate the malignant B cell clone.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Occurrence of embryotoxicity in mouse embryos following in utero exposure to 2'-deoxycoformycin (pentostatin).

Author: AirhartM J, RobbinsC M, KnudsenT B, ChurchJ K, SkalkoR G

Embryotoxicity

2'-deoxycoformycin (dCF) caused multiple abnormalities and growth retardation in mouse embryos. The exact mechanism of dCF-induced embryolethality is unclear, but evidence suggests both direct toxicity at specific embryonic sites and generalized retardation in development.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

16.

Treatment of hairy cell leukemia with deoxycoformycin (YK-176). The Deoxycoformycin (YK-176) Study Group.

Author: ShimoyamaM, TobinaiK, YamaguchiK, HirashimaK, ItohS, KonishiH, MikuniC, TogawaA, HottaT, ToyodaN

Recovery of blood cells
Remission
Appetite loss
Fatigue
Fever
Nausea
Skin rash
Vomiting

YK-176 (2'-deoxycoformycin) was highly effective in treating hairy cell leukemia (HCL), achieving a 100% remission rate in 11 patients. The treatment was generally well tolerated, with only mild to moderate side effects reported.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

[Hairy cell leukemia successfully treated with 2'-deoxycoformycin following refractoriness to splenectomy and alpha-interferon therapy].

Author: ShibataT, HottaT

Complete remission
Palliative and transient
Unsatisfactory effects

A 34-year-old man with hairy cell leukemia was successfully treated with 2'-deoxycoformycin (DCF), achieving complete remission and durable remission for more than 6 months without maintenance therapy.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Japanese

18.

Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease.

Author: CummingsF J, KimK, NeimanR S, ComisR L, OkenM M, WeitzmanS A, MannR B, O'ConnellM J

CTCL treatment
Lymphoma treatment
Fatal toxicities

2'-deoxycoformycin (pentostatin; dCF) was found to be active in treating refractory lymphomas and cutaneous T-cell lymphomas, achieving partial responses in 32% of patients. The drug should be avoided in patients with a history of serious pulmonary or cardiac disease.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

19.

Adenosine deaminase and thymocyte maturation.

Author: DohertyP J, PanS, MulloyJ C, ThompsonE, ThornerP, BarankiewieczJ, RoifmanC M, CohenA

Thymocyte destruction

Deoxycoformycin, an inhibitor of adenosine deaminase, blocked thymocyte differentiation at two points in mice, resulting in a depletion of immature cortical thymocytes and an accumulation of CD4+CD8+ thymocytes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

20.

Proliferative bone lesions in rats given anticancer compounds.

Author: CourtneyC L, KimS N, WalshK M, WatkinsJ R, DominickM A

Bone formation
Bone marrow injury
Myelostromal proliferation

Three anticancer compounds, trimetrexate glucuronate, pentostatin, and CI-980, induced proliferative endosteal lesions in rats, indicating local bone marrow injury and subsequent bone formation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

Early postimplantation embryolethality in mice following in utero inhibition of adenosine deaminase with 2'-deoxycoformycin.

Author: KnudsenT B, GrayM K, ChurchJ K, BlackburnM R, AirhartM J, KellemsR E, SkalkoR G

Decidual protection
Embryonic development arrest

Intrauterine exposure to 2'-deoxycoformycin (dCF), an ADA inhibitor, in pregnant mice resulted in a significant increase in implantation site resorptions on days 7 and 8 of gestation. dCF completely inhibited ADA activity in the antimesometrial decidua, leading to excessive cell death in the embryo and arrested development. This suggests that the antimesometrial decidua plays a crucial role in preventing the accumulation of ADA substrates in the implantation site.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

24.

Pharmacologic marrow purging in murine T cell leukemia.

Author: CopelanE A, JohnsonS C, GreverM R, SheridanJ F, TutschkaP J

Tumor cell purging

Deoxycoformycin and deoxyadenosine were effective in purging malignant T cells from murine marrow in vitro. The combination killed more than 5 logs of tumor cells while not interfering with the rescue of lethally irradiated mice. This model may be useful in developing strategies to purge malignant T cells from marrow.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

27.

Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.

Author: YamaguchiK, YulL S, OdaT, MaedaY, IshiiM, FujitaK, KagiyamaS, NagaiK, SuzukiH, TakatsukiK

Adult T-cell leukemia treatment
Gastrointestinal toxicity

Five patients with adult T-cell leukaemia (ATL) refractory to chemotherapy were treated with 2'-deoxycoformycin (DCF). Two patients showed a good response, while three were resistant. One patient in continuous remission without further therapy. The most prominent change was the drop in the leucocyte count. The only adverse effects were gastrointestinal toxicity, nausea and vomiting.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

28.

The effects of an induced adenosine deaminase deficiency on T-cell differentiation in the rat.

Author: BartonR W

Lymphocyte Development Inhibition

Inhibition of adenosine deaminase (ADA) in rats significantly inhibited thymus regeneration, suggesting that ADA deficiency affects the proliferation and differentiation of subcapsular cortical thymocytes, which are precursors of cortical and medullary thymocytes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

29.

Complete suppression of skin allograft rejection in rats treated with continuous infusion of 2'deoxycoformycin.

Author: RuersT J, BuurmanW A, van der LindenC J, KootstraG

Immunosuppression
Lymphocytotoxicity

2'deoxycoformycin (2'dcf) significantly prolonged graft survival in rats and suppressed mitogen response in lymphocytes. It was a strong immunosuppressant when given continuously.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

30.

Role of adenosine in sleep in rats.

Author: RadulovackiM

Increase REM sleep
Increase deep slow-wave sleep

Adenosine analogs increase deep slow wave sleep and REM sleep in rats. Deoxycoformycin, an inhibitor of adenosine deaminase, also increases REM and deep slow-wave sleep.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.